Oxford BioMedica (OXBDF)
(Delayed Data from OTC)
$3.79 USD
0.00 (0.00%)
Updated May 2, 2024 09:30 AM ET
4-Sell of 5 4
D Value B Growth F Momentum C VGM
Income Statements
Fiscal Year end for Oxford BioMedica falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | NA | 173 | 196 | 113 | 82 |
Cost Of Goods | NA | 88 | 83 | 53 | 46 |
Gross Profit | NA | 86 | 114 | 59 | 36 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 123 | 85 | 66 | 55 |
Income After Depreciation & Amortization | 0 | -37 | 29 | -7 | -18 |
Non-Operating Income | NA | 1 | 0 | 0 | 0 |
Interest Expense | NA | 21 | 1 | 1 | 8 |
Pretax Income | NA | -57 | 27 | -8 | -27 |
Income Taxes | NA | -1 | 1 | 0 | -6 |
Minority Interest | NA | -7 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -56 | 26 | -8 | -21 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -48 | 26 | -8 | -21 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -4 | 46 | 5 | -11 |
Depreciation & Amortization (Cash Flow) | NA | 33 | 17 | 13 | 7 |
Income After Depreciation & Amortization | 0 | -37 | 29 | -7 | -18 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | NA | 75.88 | 83.49 | 79.96 | 72.71 |
Diluted EPS Before Non-Recurring Items | NA | -0.51 | 0.31 | -0.10 | -0.28 |
Diluted Net EPS (GAAP) | NA | -0.51 | 0.31 | -0.10 | -0.28 |
Fiscal Year end for Oxford BioMedica falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | NA | NA |
Cost Of Goods | NA | NA | NA | NA | NA |
Gross Profit | NA | NA | NA | NA | NA |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Non-Operating Income | NA | NA | NA | NA | NA |
Interest Expense | NA | NA | NA | NA | NA |
Pretax Income | NA | NA | NA | NA | NA |
Income Taxes | NA | NA | NA | NA | NA |
Minority Interest | NA | NA | NA | NA | NA |
Investment Gains/Losses | NA | NA | NA | NA | NA |
Other Income/Charges | NA | NA | NA | NA | NA |
Income From Cont. Operations | NA | NA | NA | NA | NA |
Extras & Discontinued Operations | NA | NA | NA | NA | NA |
Net Income (GAAP) | NA | NA | NA | NA | NA |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | NA | NA | NA | NA | NA |